Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tanshinone IIA or pharmaceutically acceptable salt in preparation of medicament for treating or inhibiting mucus in wind pipe

A technology of pharmacy and tanshinone, which is applied to the application field of tanshinone IIA or its pharmaceutically acceptable salt in the preparation of medicine for treating or inhibiting airway mucus hypersecretion

Inactive Publication Date: 2013-04-03
THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT) +1
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, N-acetylcysteine ​​and ambroxol are commonly used clinically to inhibit hypersecretion of airway mucus. These drugs, as mucolytic drugs, can reduce the viscosity of sputum and liquefy it, thereby Promote the discharge of sputum, but this type of drug has many adverse reactions, such as nausea, vomiting, indigestion, heartburn, even coughing, bronchospasm, etc. Some patients are forced to stop this type of drug due to serious adverse drug reactions usage of

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tanshinone IIA or pharmaceutically acceptable salt in preparation of medicament for treating or inhibiting mucus in wind pipe
  • Application of tanshinone IIA or pharmaceutically acceptable salt in preparation of medicament for treating or inhibiting mucus in wind pipe
  • Application of tanshinone IIA or pharmaceutically acceptable salt in preparation of medicament for treating or inhibiting mucus in wind pipe

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0022] Example 1: Effect of Sodium Tanshinone IIA Sulfonate or a Pharmaceutically Acceptable Salt thereof on LPS-Induced Epithelial Cell MUC1 Expression Level

[0023] one, main experimental materials

[0024] 1. Human alveolar type II epithelial cell line A549 cells: purchased from the American Standard Biological Collection Center (ATCC)

[0025] 2. DMEM medium, fetal bovine serum: American Gibico Company

[0026] 3. Rabbit anti-MUC1 monoclonal antibody: Abcam, USA

[0027] 4. Goat anti-rabbit IgG: Sigma, USA

[0028] 5. Goat anti-mouse IgG: American KPL company

[0029] 6. Lipopolysaccharide (LPS): purchased from Sigma, USA

[0030] 7. Tanshinone Ⅱ A (sulfonate, purity > 99%): purchased from National Institute for the Control of Pharmaceutical and Biological Products (NICPBP)

[0031] 8. Cell lysate:

[0032] 2. Main instruments

[0033] 1. Carbon dioxide incubator: Danish Thermo company

[0034] 2. Inverted phase-contrast microscope: Leica, Germany

[003...

Embodiment 2

[0049] Example 2: Effect of Tanshinone IIA or its pharmaceutically acceptable salt on the expression of MUC1 in lung tissue of LPS-induced mucus hypersecretion mouse model

[0050] 1. Main experimental materials:

[0051] 1. SPF grade C57 mice, weighing 20-25g, Guangdong Experimental Animal Center

[0052] All the other experimental materials are the same as in Example 1

[0053] 2. Main instruments

[0054] 1. Ultrasonic Crusher: SONICS Company of the United States

[0055] 2. Tissue homogenizer: German IKA company

[0056] All the other experimental instruments are the same as in Example 1

[0057] three , experimental method

[0058] 1. Establishment of LPS-induced mucus hypersecretion mouse model

[0059] The C57 mice were randomly divided into four groups: normal control group, TIIA group, LPS group and TIIA+LPS group, each group including 6-8 mice. The dosage of tanshinone IIA sodium sulfonate injection is 25mg / kg body weight, intraperitoneal injection;...

Embodiment 3

[0069] Example 3: Effect of Tanshinone IIA or its pharmaceutically acceptable salt on the expression of MUC5AC in alveolar lavage fluid of LPS-induced mucus hypersecretion mice

[0070] one. Main experimental materials:

[0071] 1. MUC5AC antibody: American RD Company

[0072] All the other experimental materials and instruments are the same as in Example 2

[0073] two , experimental method

[0074] 1. Establishment of LPS-induced acute lung injury model

[0075] Same as Example 2

[0076] 2. Detection of MUC5AC in alveolar lavage fluid

[0077] The collected alveolar lavage fluid from each group of mice was centrifuged at low temperature, and the supernatant protein suspension was collected, and the level of extracellular fragments of MUC1 in the alveolar lavage fluid was detected by enzyme-linked immunosorbent assay (ELISA).

[0078] Experimental results: as Figure 4 As shown, the level of MUC5AC in the alveolar lavage fluid of LPS-induced mucus hypersec...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of tanshinone IIA or pharmaceutically acceptable salt in preparation of medicament for treating or inhibiting mucus in a wind pipe. The tanshinone IIA or pharmaceutically acceptable salt can obviously inhibit the hypersecretion of mucoprotein in the wind pipe of the lung tissue. Compared with the commonly used mucolytic agents, the tanshinone IIA or pharmaceutically acceptable salt can obviously inhibit the expression and the secretion of mucoprotein, and the obvious side and toxic effects can not be found.

Description

technical field [0001] The invention relates to a new application of tanshinone IIA, in particular to the application of tanshinone IIA (TIIA) or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating or inhibiting airway mucus hypersecretion. Background technique [0002] Airway mucus is a complex distributed on the inner surface of airways and alveoli secreted by airway epithelial cells, alveolar type II epithelial cells, and glandular cells, including water, electrolytes, and various organic compounds. Mucin is a high-molecular-weight glycoprotein and the most important component of mucus, which determines the physical and biological (protective) properties of mucus aggregation, viscosity, viscoelasticity, and lubricity. So far, a total of 21 mucins have been found, named after different numbers after MUC, 12 of which are expressed in the airway, including MUC1, 2, 4, 5AC, 5B, 7, 8, 11, 13, 16, 19 , and 20, where MUC1 and MUC5AC are major...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/58A61P11/00
Inventor 卢文菊王健张科东徐小明张晨婷陈豫钦
Owner THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIV (GUANGZHOU RESPIRATORY CENT)
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com